Practical Implementation of Third-Line Therapies for Refractory Overactive Bladder (OAB) Webcast (2024)

Learners will be presented with case-based and guidelines-based information regarding when to introduce third-line therapies to patients for potentially refractory overactive bladder (OAB), presentation (scripting) techniques to impart important information to patients with user-friendly comprehensible language and analogies to help the patients receive the counseling, pros and cons of each of the third-line therapies, technical tips on optimal delivery of the three third-line therapies and how to select which therapies are the best fit for a given patient. The format, again, will be case based, but also conversational and interactive, with the use of the audience response system and encouragement for live real-time audience discussion.


This educational activity is supported by independent educational grants from:


Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Discuss the third-line therapies available to treat OAB refractory to conservative techniques.
  2. Effectively provide counseling regarding advanced treatment techniques with "friendly, nonthreatening" language that does not intimidate the patients.
  3. Consider helpful techniques to optimize lead placement for sacral neuromodulation and be comfortable with troubleshooting the device.
  4. Incorporate caveats that are important in the delivery of injections in the bladder for treatment of OAB. 
  5. Incorporate peripheral nerve stimulation options, including the traditional and newer techniques that will be discuss in detail, into their practice as they see fit. 
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
Course expires: 


NameCompany NameRelationship TypeEnd Date
Ginsberg, David AlanCalderaConsultant or Advisor10/31/2023
AvationConsultant or Advisor09/17/2022
MedtronicMeeting Participant or Lecturer09/20/2022
Kobashi, Kathleen ChizukoAllerganConsultant or AdvisorCurrent
MedtronicConsultant or AdvisorCurrent
Vasavada, Sandip PrasanMedtronicMeeting Participant or LecturerCurrent
BlueWindConsultant or AdvisorCurrent



PDF iconEducation Council Disclosures


PDF iconCOI Review Work Group Disclosures

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Method of Participation: Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Release Date: May, 2024
Expiration Date: May, 2025

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. 

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.


Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.